Skip to main
ALMS

Alumis Inc (ALMS) Stock Forecast & Price Target

Alumis Inc (ALMS) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Alumis is expected to see success with its TYK2 inhibitors, envudeucitinib and A-005, as it moves towards patient testing and a potential NDA submission for envu in psoriasis in 4Q26. The company has a strong cash position with $502.3M in cash and investments and a runway into 4Q27, giving it the financial flexibility to pursue its pipeline and explore strategic alternatives for lonigutamab. However, risks include potential delays in regulatory filings, competition, and possible equity dilution risk.

Bears say

Alumis is facing a number of risks and uncertainties that lead to a negative outlook on the stock. Their prospects for expansion beyond their initial psoriasis indication are heavily dependent on the results of the upcoming LUMUS trial. If this trial does not show convincing results in SLE, a notoriously difficult disease to treat, Alumis may fail to establish the credibility of their TYK2 inhibitor approach and struggle to compete with other oral therapies in the market. Additionally, there is competition from other biopharmaceutical companies with similar therapies and Alumis may face challenges in commercializing their products without a suitable partner. Furthermore, any regulatory obstacles could lead to downward revisions in projections and impact the stock's performance.

Alumis Inc (ALMS) has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alumis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alumis Inc (ALMS) Forecast

Analysts have given Alumis Inc (ALMS) a Buy based on their latest research and market trends.

According to 9 analysts, Alumis Inc (ALMS) has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alumis Inc (ALMS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.